<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660800</url>
  </required_header>
  <id_info>
    <org_study_id>CTAP101-CL-1020</org_study_id>
    <nct_id>NCT03660800</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects</brief_title>
  <official_title>An Open-label, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Oral CTAP101 (Calcifediol) Extended-release Capsules in Japanese and Non-Japanese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and non-Japanese Healthy&#xD;
      Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Oral CTAP101&#xD;
      (Calcifediol) Extended-release Capsules in Japanese and non-Japanese Healthy Subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Actual">January 22, 2019</completion_date>
  <primary_completion_date type="Actual">October 24, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related AEs as assessed by industry standards</measure>
    <time_frame>8 weeks</time_frame>
    <description>Incidence of AEs will be summarized by arm for all treatment-emergent AEs. Number and percent of participants with AEs will be summarized by system organ class and preferred term and presented overall and by arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in baseline of peak plasma concentration</measure>
    <time_frame>8 weeks</time_frame>
    <description>Baseline finding will be measured against the different time points collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mean total of the different components of calcifediol</measure>
    <time_frame>8 weeks</time_frame>
    <description>Descriptive statistics will be calculated for PD assessment in the per protocol population.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Vitamin D Insufficiency</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 450mcg/weekly fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 1800mcg/weekly fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTAP101 Capsules</intervention_name>
    <description>Calcifediol Extended-Release Capsules</description>
    <arm_group_label>CTAP101 Capsules 1800mcg/weekly fasted</arm_group_label>
    <arm_group_label>CTAP101 Capsules 450mcg/weekly fasted</arm_group_label>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly fasted</arm_group_label>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants are eligible to be included in the study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
          1. Signed the informed consent form as described in Appendix 3 which includes compliance&#xD;
             with the requirements and restrictions listed in the informed consent form (ICF) and&#xD;
             in this protocol&#xD;
&#xD;
          2. Willing and able to comply with study instructions and to commit to all study days&#xD;
&#xD;
          3. Man or woman, 18 to 55 years of age inclusive at the time of signing the informed&#xD;
             consent form&#xD;
&#xD;
          4. Overtly healthy as determined by medical evaluation including medical history,&#xD;
             physical examination, clinical laboratory tests&#xD;
&#xD;
          5. Body mass index (BMI) within 18.0 to 30.0 kg/m2 (inclusive) and body weight not less&#xD;
             than 50 kg&#xD;
&#xD;
          6. Blood pressure (after at least 2 minutes of rest) between 90 and 140 mmHg systolic,&#xD;
             inclusive, and no higher than 90 mmHg diastolic.&#xD;
&#xD;
          7. A 12-lead ECG consistent with normal cardiac conduction and function, including:&#xD;
&#xD;
               -  Sinus rhythm&#xD;
&#xD;
               -  Pulse rate between 40 and 100 beats per minute (bpm)&#xD;
&#xD;
               -  QTc interval â‰¤450 milliseconds (QT interval corrected using Fridericia correction&#xD;
                  method [QTcF]&#xD;
&#xD;
               -  QRS interval of &lt;120 milliseconds&#xD;
&#xD;
               -  PR interval &lt;200 milliseconds&#xD;
&#xD;
               -  Morphology consistent with healthy cardiac conduction and function&#xD;
&#xD;
          8. Must have negative tests for drugs of abuse at Screening and Day -2&#xD;
&#xD;
          9. Must have a negative alcohol test at Screening and Day -2&#xD;
&#xD;
         10. Must have adequate venous access in both arms, in the opinion of the Investigator&#xD;
&#xD;
         11. Has a screening serum total 25-hydroxyvitamin D level between 10 and 40 ng/mL,&#xD;
             inclusive&#xD;
&#xD;
         12. If male, must agree to use contraception as detailed in Appendix 5 of this protocol&#xD;
             during the treatment period and for at least 3 months after the last dose of study&#xD;
             treatment and refrain from donating sperm during this period&#xD;
&#xD;
         13. If female, be sterile (ie, at least 1 month post-surgical sterilization, confirmed&#xD;
             nonsurgical sterilization or at least 6 months post-menopausal [as determined by&#xD;
             follicle stimulating hormone (FSH) / estradiol testing]); or who are of childbearing&#xD;
             potential but are abstinent, have a surgically sterile partner (ie, at least 6 months&#xD;
             postvasectomy), or are using a copper intrauterine device or a combination of at least&#xD;
             2 acceptable barrier methods such as condom + intravaginal spermicide, diaphragm +&#xD;
             intravaginal spermicide, or cervical cap + intravaginal spermicide. Contraceptive&#xD;
             medications (oral or by other routes) containing steroid hormones are not allowed.&#xD;
             Women of childbearing potential must not be lactating and must have a negative&#xD;
             pregnancy test at screening and Day -2, and agree to continue their accepted method of&#xD;
             contraception throughout the study. See guidance on contraceptives in Appendix 5.&#xD;
             Additional Inclusion Criteria for Japanese Participants Only&#xD;
&#xD;
        1. Be first generation Japanese defined as:&#xD;
&#xD;
          -  Born in Japan&#xD;
&#xD;
          -  Has 2 Japanese biological parents and 4 Japanese biological grandparents&#xD;
&#xD;
          -  Has lived outside of Japan for less than 5 years&#xD;
&#xD;
          -  Has made no significant changes in lifestyle, including diet, since leaving Japan&#xD;
             Additional Inclusion Criteria for non-Japanese Participants Only&#xD;
&#xD;
               1. Not of Japanese or Asian descent&#xD;
&#xD;
               2. Parents and grandparents not born in Japan or in any Asian countries Note:&#xD;
                  Retesting of abnormal lab values that may lead to exclusion will be allowed once.&#xD;
&#xD;
        Retesting will take place during an unscheduled visit during the screening phase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          1. Has taken a Vitamin D supplement within 28 days prior to dosing&#xD;
&#xD;
          2. Has a medically confirmed history of kidney stones within the previous 2 years&#xD;
&#xD;
          3. Has a urine calcium: creatinine ratio &gt; 0.2 at the Screening visit&#xD;
&#xD;
          4. Has a known or suspected hypersensitivity to any of the constituents of the&#xD;
             investigational products&#xD;
&#xD;
          5. Has a history of or current clinically significant medical illness including but not&#xD;
             limited to, cardiac arrhythmias or other cardiac disease; hematologic disease;&#xD;
             coagulation disorders (including any abnormal bleeding or blood dyscrasias); lipid&#xD;
             abnormalities; significant pulmonary disease, including bronchospastic respiratory&#xD;
             disease; diabetes mellitus; hepatic or renal insufficiency (creatinine clearance below&#xD;
             60 mL/min); thyroid disease; neurologic or psychiatric disease; infection; or any&#xD;
             other illness that the investigator considers should exclude the participant or that&#xD;
             could interfere with the interpretation of the study results.&#xD;
&#xD;
          6. Clinically significant abnormal values for hematology, clinical chemistry, or&#xD;
             urinalysis at screening as deemed appropriate by the investigator&#xD;
&#xD;
          7. Clinically significant abnormal physical examination, vital signs or 12 lead ECG at&#xD;
             screening as deemed appropriate by the investigator&#xD;
&#xD;
          8. Has a history of human immunodeficiency virus (HIV) antibody positive, or tests&#xD;
             positive for HIV; has a history of hepatitis B surface antigen (HBsAg) or hepatitis C&#xD;
             antibody (anti-HCV) positive, or other clinically active liver disease, or tests&#xD;
             positive for HBsAg or anti-HCV at Screening.&#xD;
&#xD;
          9. Has received an investigational drug or used an invasive investigational medical&#xD;
             device within 1 month or within a period less than 10 times the drug's half-life,&#xD;
             whichever is longer, before Day 1.&#xD;
&#xD;
         10. Has donated 1 unit (450 mL) or more of blood or plasma within 30 days of dosing&#xD;
&#xD;
         11. Has an acute illness within 5 days prior to the first dose of study medication&#xD;
&#xD;
         12. Has received any prescribed systemic or topical medication within 14 days of dosing,&#xD;
             received a vaccination within 30 days of dosing, or taken any nonprescription systemic&#xD;
             or topical medication or herbal preparation within 7 days of dosing (exception:&#xD;
             occasional use of acetaminophen or ibuprofen at nonprescription doses).&#xD;
&#xD;
         13. History of drug or alcohol use disorder according to Diagnostic and Statistical Manual&#xD;
             of Mental Disorders (5th edition) criteria within 5 years before Screening or positive&#xD;
             test result(s) for alcohol and/or drugs of abuse (including prescription drugs such as&#xD;
             stimulants, opioids, and benzodiazepines) at Screening or at Admission on Day -2&#xD;
&#xD;
         14. Has an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level &gt;1.5&#xD;
             times the upper limit of normal (ULN), active liver disease or jaundice at Screening&#xD;
             or Day -2&#xD;
&#xD;
         15. Is considering or has preplanned surgery or procedures that would interfere with the&#xD;
             conduct of the study&#xD;
&#xD;
         16. Is an employee of the investigator or study site, with direct involvement in the&#xD;
             proposed study or other studies under the direction of that investigator or study&#xD;
             site, as well as family members of the employees or the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Mussallem</last_name>
    <role>Study Chair</role>
    <affiliation>WCCT Global, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global, Inc.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

